|
Year:
1999
| Volume: 7
| Issue: 4
| Pages: 177-179
|
|
Case Report |
|
TREATMENT OF MALIGNANT PARAGANGLIOMA IN ZUCKERKANDL'S REGION WITH 131-I-MIBG
Milica MALESEVIC, Zlatko SELIR, Dolores SRBOVAN, Vera POPOVIC, Radovan JANKOVIC, Andrej GROSSMAN, Ivana ZAGAR |
|
DOI:
|
|
Abstract: |
|
The patient we report on is a 27 years old female, who has been suspected for malignant paraganglioma on the basis of clinical observation, CT and increased values of catecholamine (products) in urine. The patient was surgically treated on October 28, 1996 and a tumor located retroperitoneally left in Zuckerkandlís region was detected. Pathohistologic finding confirmed malignant paraganglioma. Metastases in thoracic and lumbar part of spine and in pelvis were found postoperatively by means of MRI and dg. scintigraphy (dg.sc.) 131-I-MIBG. A conclusion has been made to start additional treatment with 131-I-MIBG for the purpose of metastases elimination. The patient received the first 131-I-MIBG dosage of 7.4 GBq in London, on February 10, 1997. Dg.sc. 131-I-MIBG, performed one year later, located metastases on the same place. A decision was made to apply an additional 131-I-MIBG dosage of 7.4 GBq. The therapy was administered at the Institute of Oncology Sremska Kamenica, on March 27, 1998. Upon a new dg.sc. 131-I-MIBG, the patient received the third 131-I-MIBG dosage of 7.4 GBq, on November 11, 1999. This paper presents a detailed procedure of 131-I-MIBG application, prevention of a serious complication, catecholamine crisis, as well as the methodology of dosimetric measurements aimed at the protection of medical personnel and population and the management of patients. |
|
Key words:
Malignant paraganglioma; Therapy; 131-I-MIBG (meta-iodobenzylguanadine) |
|
Read
full text in PDF [Full
Text] |
|
|